Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 10,552 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Not listed No phase listed Observational

Genetic Study of Insulin-Like Growth Factor-I Receptor Mutations in Patients With Intrauterine Growth Retardation

NCT00005105
View directory record Official record
Conditions
Intrauterine Growth Retardation
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Months to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
5
States / cities
Atlanta, Georgia • Indianapolis, Indiana • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients

NCT03015259
View directory record Official record
Conditions
Asthma
Interventions
Budesonide/Formoterol fumarate dihydrate, Symbicort, Placebo
Drug
Lead sponsor
Kindeva Drug Delivery
Industry
Eligibility
18 Years and older
Enrollment
1,762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
95
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

NCT01968980
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia
Interventions
Bococizumab (PF-04950615;RN316), Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
22
States / cities
Los Angeles, California • Hartford, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

NCT01178346
View directory record Official record
Conditions
Smoking Cessation
Interventions
NicVAX vaccine, Placebo
Biological
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Tucson, Arizona • Encino, California • Los Alamitos, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

NCT01427270
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
170
States / cities
Alabaster, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2014 · Synced Nov 4, 2026, 2:59 PM EST
Not listed Not applicable Interventional

Inspire® Post-Approval Study / Protocol Number 2014-001

NCT02413970
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Inspire® UAS System
Device
Lead sponsor
Inspire Medical Systems, Inc.
Industry
Eligibility
22 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Nov 4, 2026, 2:59 PM EST
Completed No phase listed Observational

Role of Placenta Growth Factor in Sickle Acute Chest Syndrome

NCT00448370
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
66 Months to 30 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional

Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)

NCT00419705
View directory record Official record
Conditions
Ischemic Stroke
Interventions
NeuroThera® Laser System
Device
Lead sponsor
PhotoThera, Inc
Industry
Eligibility
40 Years to 90 Years
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
51
States / cities
Fort Smith, Arkansas • Berkeley, California • Encinitas, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Nov 4, 2026, 2:59 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Intismeran autogene, Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
68
States / cities
Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)

NCT00642460
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Hartford, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Nov 4, 2026, 2:59 PM EST
Recruiting No phase listed Observational

Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry

NCT02249923
View directory record Official record
Conditions
Pulmonary Vascular Disease, Pulmonary Arterial Hypertension
Interventions
Not listed
Lead sponsor
New York Medical College
Other
Eligibility
1 Day to 21 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
13
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Nov 4, 2026, 2:59 PM EST
Completed Not applicable Interventional Results available

Comparing Auto-adjustable Positive Airway Pressure to Continuous Positive Airway Pressure in Children With Sleep Apnea

NCT01846988
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
crossover treatment (REMstar Auto A-Flex)
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 20 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 2Phase 3 Interventional Results available

Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus

NCT02143973
View directory record Official record
Conditions
Uremic Pruritus, Pruritus
Interventions
nalbuphine HCl ER
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

NCT01793883
View directory record Official record
Conditions
Influenza
Interventions
40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
18 Years to 64 Years
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
70
States / cities
Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

NCT00002646
View directory record Official record
Conditions
Breast Cancer
Interventions
fenretinide, tamoxifen citrate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
85
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

NCT00000903
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
49
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Nov 4, 2026, 2:59 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hybrid Effectiveness-Implementation Study to Improve Clopidogrel Adherence

NCT01609842
View directory record Official record
Conditions
Cardiovascular Disease, Acute Coronary Syndrome
Interventions
Multifaceted Intervention with pharmacist and IVR
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 91 Years
Enrollment
14,573 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
15
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Nov 4, 2026, 2:59 PM EST
Terminated Phase 2 Interventional Results available

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

NCT03834220
View directory record Official record
Conditions
Solid Tumor
Interventions
Debio 1347
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • La Jolla, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Nov 4, 2026, 2:59 PM EST
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962
View directory record Official record
Conditions
Focal Epilepsy
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
54
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

Pediatric Arthritis Study of Certolizumab Pegol

NCT01550003
View directory record Official record
Conditions
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Interventions
Certolizumab Pegol (CZP)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia

NCT01288469
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Atorvastatin, Placebo (for atorvastatin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
20
States / cities
Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional Results available

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

NCT03996369
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrasimod, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
16 Years to 80 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
62
States / cities
Dothan, Alabama • Mobile, Alabama • Sun City, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Nov 4, 2026, 2:59 PM EST
Completed Phase 3 Interventional

A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine

NCT00000720
View directory record Official record
Conditions
HIV Infections
Interventions
Globulin, Immune, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
48
States / cities
Downey, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 4, 2026, 2:59 PM EST